Last updated: May 23, 2026
What suppliers make vadadustat (API, intermediates, and finished tablets)?
Answer: Public, reliably sourced vendor-level information on vadadustat API, key intermediates, and tablet manufacturing is not present in the provided materials. Producing a supplier list without verifiable sourcing would risk incorrect attribution.
Why supplier claims are high-risk for vadadustat
- Vadadustat is marketed as a prescription small molecule and is regulated under GMP. Supplier lists depend on evidence that is typically found in NDAs, FDA inspections, Drug Master Files (DMFs), investigator statements, regulatory filings, and API traceability disclosures.
- Without those sources in the input, any “supplier” roster would be speculative.
Which companies supply vadadustat API and DMFs?
Answer: No verified API/DMF supplier mappings are provided in the input.
Common places validated supplier data appears
- FDA DMF holders and cross-references (for validated suppliers)
- Public GMP inspection outcomes tied to API sites
- ANDA/BLA application exhibits referencing API manufacturers
- Contract manufacturing disclosures in regulatory submissions
None of the above is included in the provided materials, so no supplier table can be compiled.
What CDMOs manufacture vadadustat tablets and who fills commercial product?
Answer: No validated CDMO or finished-dose manufacturing sites are provided in the input.
Finished-dose supply chain elements that require sourcing
- Drug product manufacturing (tableting, coating, packaging)
- Primary packaging component sourcing
- Quality control release testing sites
- Sterility or aseptic controls (not typically relevant for tablets, but other release disciplines are)
No site-specific evidence is provided.
How does the supply chain differ by geography for vadadustat?
Answer: No country-specific supply chain disclosures are provided in the input.
Geography-specific factors that affect supplier identification
- Local regulatory registrations
- Tendered hospital supply contracts
- Parallel distribution constraints
- Site GMP status with national regulators
None of these data are present.
What supply risks exist for vadadustat (single-source API, intermediate bottlenecks, GMP issues)?
Answer: No evidence-backed supply risk profile is provided in the input, so an accuracy-safe risk analysis cannot be produced.
Evidence needed to quantify risk
- Supplier count per manufacturing stage (API vs intermediates vs drug product)
- Published GMP inspection observations
- DMF status events (withdrawals, amendments, rejections)
- Batch failure history and recalls
Not provided.
What does the supplier landscape imply for generic or biosimilar competition?
Answer: Vadadustat generic competition is driven by regulatory and IP posture and by ability to source/qualify API and drug product manufacturing. No validated supplier list is provided, so the practical impact of supplier bottlenecks cannot be tied to named companies.
What matters in practice
- Ability to access commercial API versus reverse-engineered routes
- DMF availability for cross-reference
- Drug product formulation and process equivalence at scale
No named supplier pathways are available in the input.
Vadadustat supplier table (API, intermediates, drug product): what can be listed from the provided materials?
Answer: No supplier entries can be listed without sourcing.
| Component |
Supplier name |
Location (site/country) |
Evidence basis (e.g., DMF/filing/inspection) |
| API |
Not provided |
Not provided |
Not provided |
| Key intermediates |
Not provided |
Not provided |
Not provided |
| Finished tablets |
Not provided |
Not provided |
Not provided |
| Packaging/fill |
Not provided |
Not provided |
Not provided |
Key Takeaways
- No verified vadadustat suppliers (API/DMF holders, intermediate manufacturers, or tablet CDMOs) are available in the provided materials.
- A supplier list would require document-backed attribution such as FDA DMF disclosures, FDA inspection records tied to specific sites, or regulatory filing exhibits.
- Without those sources in the input, naming companies would risk inaccuracies.
FAQs
-
Who are the vadadustat API manufacturers listed in FDA records?
Not determinable from the provided materials.
-
Are there vadadustat DMF holders for cross-reference filings?
Not determinable from the provided materials.
-
Which CDMOs make vadadustat tablets and where are the drug product sites located?
Not determinable from the provided materials.
-
Is vadadustat produced by single-source API suppliers or multiple vendors?
Not determinable from the provided materials.
-
What manufacturing or GMP issues could disrupt vadadustat supply?
Not determinable from the provided materials.
References
(0) No citable sources were provided in the input.
